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Objectives:  To  estimate  seroprevalence  of  11 high-risk  (hr)  HPV  types  and  four low-risk  (lr)  HPV  types
among  20–64  years  old  Slovenian  women  participating  in  the  population-based  cervical  cancer  screening
program.
Methods:  Serum  samples  from  3259  women  were  tested  for  HPV  type-speciﬁc  antibodies  with  a  multi-
plexed  pseudovirion-based  serological  assay  (PsV-Luminex).
Results: Seropositivity  for any  of the  15 HPV  types  was  65.7%,  any  of the  11 hr-HPV  types  59.2%,  and  any  ofPV
eroprevalence
ross-sectional study
lovenia
the  four  lr-HPV  types  33.1%.  Antibodies  against  at least  one  of the  four vaccine  HPV  types  (HPV 6,  11,  16,
18)  were  detected  in  40.8%  women.  Among  hr-HPV  types,  seropositivity  was  highest  for  HPV  16  (25.2%)
and  among  lr-HPV  types  for HPV  6 (19.1%).  Age-speciﬁc  HPV16  seropositivity  was  highest  among  30–39
years  old (29.6%)  and  decreased  with  increasing  age to  14.0%  among  60–64  years  old.
Conclusion: The  lifetime  sexual  exposure  to genital  HPV  types  is substantial,  emphasising  the  need  for
HPV  vaccination.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Genital human papillomavirus (HPV) types cause the most com-
on sexually transmitted infection [1]. High-risk (hr) HPV types
ause cervical cancer in women and other cancers in both gen-
ers [1,2] and low-risk (lr) HPV types genital warts and recurrent
espiratory papillomatosis [3]. HPV DNA detection is the standard
ethod for diagnosing current cervical infection of which most
lear or became undetectable within two years [4]. Approximately
0% of women with detectable HPV DNA in cervical smears do
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Open access under CC BY-NC-NDnot have a detectable type-speciﬁc HPV antibodies [5–8]. When
a detectable serum antibody response to the viral major capsid
protein L1 occurs, it remains relatively stable [5]. Thus, measuring
HPV type speciﬁc antibodies can be a useful, although imperfect,
tool for estimating cumulative HPV type speciﬁc lifetime exposure.
To date, there were relatively few HPV seroepidemiological stud-
ies conducted among general female populations and they were
mostly restricted to estimating seropositivity for HPV 6, 11, 16, and
18 [9–14].
Two  vaccines against HPV infection have been licensed, the
quadrivalent containing L1 virus-like particles for types 6, 11, 16
and 18 and bivalent containing L1 virus-like particles for types 16
and 18. Vaccination of 11–12 years old girls with quadrivalent vac-
cine was  introduced in Slovenia in 2009 in the absence of data on
the current prevalence and lifetime risk for HPV infections in the
population.
In 2010, we  conducted the Slovenian HPV prevalence survey
(SHPVS) among women  screened for cervical cancer to estimate
the pre-vaccination prevalence of cervical infections (HPV DNA
 license.
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Table  1
Seropositivity (%) for 15 HPV types overall and according to age groups among 3259 women  screened for cervical cancer, Slovenia, 2010.
HPV types All women (N = 3259) Age groups
20–29 (N = 945) 30–39 (N = 1171) 40–49 (N = 707) 50–64 (N = 436)
N S (%) 95% CI N S (%) N S (%) N S (%) N S (%)
HPV 2141 65.7 64.0–67.3 592 62.6 812 69.8 462 65.3 269 61.7
Single  HPV 664 20.4 19.0–21.7 180 19.0 256 21.9 139 19.7 89 20.4
Multiple  HPV 1477 45.3 43.6–47.0 412 43.6 562 48.0 323 45.7 180 41.3
hr-HPV  1930 59.2 57.5–60.9 535 56.6 750 64.0 407 57.6 238 54.6
Single  hr-HPV 497 15.2 14.0–16.4 134 14.2 204 17.4 96 13.5 63 14.4
Multiple  hr-HPV 1433 44.0 42.3–45.7 401 42.4 546 46.6 311 44.0 175 40.1
Only  hr-HPV 1062 32.6 31.0–34.2 291 30.8 405 34.6 235 33.2 131 30.0
HPV16  or 18 976 29.9 28.3–31.5 258 27.3 412 35.2 200 28.3 106 24.3
HPV16  and 18 151 4.6 3.9–5.3 46 4.9 64 5.5 21  3.0 20 4.6
HPV16  820 25.2 23.7–26.6 217 23.0 347 29.6 164 23.0 92 21.1
HPV18  307 9.4 8.4–10.4 87 9.2 129 11.0 57 8.1 34 7.8
HPV31  564 17.3 16.0–18.6 153 16.2 214 18.3 125 17.7 72 16.5
HPV33  365 11.2 10.1–12.3 113 12.0 134 11.4 70 9.9 48 11.0
HPV35  406 12.5 11.3–13.6 127 13.4 154 13.1 86 12.2 39 8.9
HPV39  570 17.5 16.2–18.8 162 17.1 212 18.1 123 17.4 73 16.7
HPV45  185 5.7 4.9–6.5 39 4.1 75 6.4 50 7.1 21 4.8
HPV52  303 9.3 8.3–10.3 92 9.7 123 10.5 61 8.6 27 6.2
HPV56  340 10.4 9.4–11.5 96 10.2 130 11.1 72 10.2 42 9.6
HPV58  640 19.6 18.3–21.0 177 18.7 254 21.7 127 18.0 82 18.8
HPV59  409 12.5 11.4–13.7 127 13.4 154 13.1 77 11.0 51 11.7
lr-HPV  1079 33.1 31.5–34.7 301 31.8 413 35.3 227 32.1 138 31.6
Single  lr-HPV 167 5.1 4.4–5.9 46 4.9 52 4.4 43 6.1 26 6.0
Multiple  lr-HPV 912 28.0 26.4–29.5 255 27.0 361 30.8 184 26.0 112 25.7
Only  lr-HPV 211 6.5 5.6–7.3 57 6.0 68 5.8 55 7.8 31 7.1
HPV6  or 11 681 20.9 19.5–22.3 194 20.5 248 21.2 155 21.9 84 19.3
HPV6  and 11 130 4.0 3.3–4.7 32 3.4 41 3.5 35 4.9 22 5.0
HPV6  622 19.1 17.7–20.4 183 19.4 230 19.6 139 19.7 70 16.1
HPV11  189 5.8 5.0–6.6 43 4.5 59 5.0 51 7.2 36 8.3
HPV68  397 12.2 11.1–13.3 108 11.4 153 13.1 78 11.0 58 13.3
HPV73  404 12.4 11.3–13.5 108 11.4 174 14.9 78 11.0 44 10.1
HPV  6 or 11 or 16 or 18 1331 40.8 39.1–42.5 366 38.7 531 45.3 282 39.9 152 34.9
HPV  6 and 11 and 16 and 18 30  0.9 0.6–1.2 11 1.2 9 0.8 6 0.8 4 0.9
HPV  not in bivalent vaccine 2578 79.1 77.7–80.5 751 79.5 923 78.8 552 78.1 352 80.7
HPV  not in quadrivalent vaccine 1928 59.2 57.5–60.8 579 61.3 640 54.6 425 60.1 284 65.1
Due to antibodies to multiple HPV types present in the serum of one woman the sums may  not add up.
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dPV:  human papillomavirus; N: number of seropositive women; S: seropositivity; 
r-HPV  types: high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59 (Group 1
r-HPV types: low-risk HPV types (6, 11, 68, 73).
ositivity) with hr-HPV and lr-HPV types [15] and to obtain esti-
ates of seroprevalences for 11 hr-HPV types and four lr-HPV
ypes.
. Methods
We  conducted a cross-sectional study among 20–64 years old
omen screened for cervical cancer within a convenience sample of
2 outpatient gynaecology services with nationally wide geograph-
cal coverage as described previously [15,16]. Brieﬂy, they were
nrolled consecutively during the study period. Cervical smear
pecimens obtained from each participant were sent to certiﬁed
ytological laboratories. In addition, cervical smear specimens were
btained for HPV DNA testing and blood specimens for HPV sero-
ogy testing. Information about vaccination against HPV and the
umber of lifetime male sexual partners was collected anony-
ously.
Whole blood samples (5 mL)  were stored at +4 ◦C for less than
 week before centrifugation for 5 min  at 3000 rpm. The serum
as aliquoted and stored at -30 ◦C until further analysis. Sero-
ogy testing was performed with a multiplexed pseudovirion-based
erological assay, as described previously [8]. Brieﬂy, pseudovirions
or 15 HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68, 73
ere used to detect seropositivity for indicated HPV types. Pseu-
ovirions were generated by transfection of 293TT cells [17]. To
eﬁne seropositivity, cut-off values were calculated independentlyﬁdence interval.
e IARC Monograph Working Group with the exception of HPV 51)).
for  each HPV type by analysing mean ﬂuorescence intensity unit
(MFI) values for 133 sera from children aged less than 12 years.
The global HPV LabNet recommended cut-off algorithm [18] was
applied: mean MFI  value of a negative control serum panel plus 3
standard deviations. If the calculated cut-off value was less than
400 MFI, the 400 MFI  was  used as cut-off.
Statistical analyses were performed using the STATA package
version 10.0 (Stata Statistical Software: release 10.0 College Station.
TX: Stata Corporation). We  estimated the HPV seropositivity with
95% conﬁdence intervals (CI) for selected HPV types (overall,
according to age and according to cytology result) and odds of sero-
positivity with 95% CI in women  with pathological cytology result
against odds among those with normal cytology result. Chi-square
test and/or test for linear trend was  used to assess the associa-
tion between seropositivity and age groups and seropositivity and
cytology results.
The  study has been carried out in accordance with the code of
Ethics of the World Medical Association (Declaration of Helsinki)
and has been approved by the Medical Ethics Committee of the
Republic of Slovenia (Consent number: 83/11/09).
3. ResultsAmong 4514 participants (survey response: 98.1%), 3321
(73.6%) contributed a blood specimen. We  excluded 62 women
because they were not 20–64 years old or information on age was
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Table 2
Seropositivity (%) for different hr-HPV types by cytology result among 3230 women  screened for cervical cancer, Slovenia, 2010.
HPV types Cytology result P trend
NILM (N = 3088) ASC-US (N = 69) LSIL (N = 51) HSIL (N = 22)
N S (%) 95% CI ORa N S (%) 95% CI OR 95% CI N S (%) 95% CI OR 95% CI N S (%) 95% CI OR 95% CI
hr-HPV 1802 58.3 56.6–60.1 1 52 75.4 64.9–85.8 2.2 1.2–3.8 41 80.4 69.1–91.7 2.9 1.4–5.9 17 77.3 58.2–96.3 2.4 0.9–6.6 <0.001
Single  hr-HPV 466 15.1 13.8–16.3 1 16 23.2 13.0–33.4 1.7 1.0–3.0 8 15.7 5.3–26.0 1.0 0.5–2.3 4 18.2 0.7–35.7 1.2 0.4–3.7 0.312
Multiple  hr-HPV 1336 43.3 41.5–45.0 1 36 52.2 40.1–64.3 1.4 0.9–2.3 33 64.7 51.1–78.3 2.4 1.3–4.3 13 59.1 36.8–81.4 1.2 0.8–4.4 <0.001
Only  hr-HPV 989 32.0 30.4–33.7 1 30 43.5 31.5–55.5 1.6 1.0–2.6 23 45.1 31.0–59.2 1.7 1.0–3.0 10 45.4 22.8–68.0 1.8 0.8–4.1 0.004
HPV16  or 18 908 29.4 27.8–31.0 1 26 37.7 25.9–49.4 1.4 0.9–2.4 24 47.1 32.9–61.2 2.1 1.2–3.7 11 50.0 28.3–72.7 2.4 1.0–5.6 <0.001
HPV16  and 18 138 4.5 3.7–5.2 1 3 4.3 0.0–9.3 1.0 0.3–3.1 6 11.8 2.6–20.9 2.8 1.2–6.8 3 13.6 0.0–29.2 3.4 1.0–11.5 0.004
HPV16  764 24.7 23.2–26.3 1 23 33.3 21.9–44.7 1.5 0.9–2.5 20 39.2 25.3–53.1 2.0 1.1–3.5 9 40.9 18.6–63.2 2.1 0.9–4.9 0.001
HPV18  282 9.1 8.1–10.1 1 6 8.7 1.9–15.5 0.9 0.4–2.2 10 19.6 8.3–30.9 2.4 1.2–4.9 5 22.7 3.7–41.7 2.9 1.1–8.0 0.002
HPV31  516 16.7 15.4–18.0 1 23 33.3 21.9–44.7 2.5 1.5–4.1 11 21.6 9.9–33.2 1.4 0.7–2.7 7 31.8 10.7–52.9 2.3 0.9–5.7 0.002
HPV33  337 10.9 9.8–12.0 1 8 11.6 3.8–19.3 1.1 0.5–2.2 11 21.6 9.9–33.2 2.2 1.1–4.4 5 22.7 3.7–41.7 2.4 0.9–6.5 0.006
HPV35  380 12.3 11.1–13.5 1 11 15.9 7.0–24.8 1.3 0.7–2.6 10 19.6 8.3–30.9 1.7 0.9–3.5 1 4.5 0.0–14.0 0.3 0.1–2.5 0.522
HPV39  526 17.0 15.7–18.4 1 14 20.3 10.5–30.0 1.2 0.7–2.2 13 25.5 13.1–37.9 1.7 0.9–3.1 8 36.4 14.5–58.2 2.8 1.2–6.7 0.005
HPV45  170 5.5 4.7–6.3 1 7 10.1 2.8–17.4 1.9 0.9–4.3 3 5.9 0.0–12.6 1.1 0.3–3.4 3 13.6 0.0–29.2 2.7 0.8–9.2 0.082
HPV52  280 9.1 8.0–10.1 1 9 13.0 4.9–21.2 1.5 0.7–3.1 10 19.6 8.3–30.9 2.4 1.2–4.9 2 9.1 0.0–22.1 1.0 0.2–4.3 0.037
HPV56  308 10.1 8.9–11.0 1 13 18.8 9.4–28.3 2.1 1.1–3.9 12 23.5 11.5–35.6 2.8 1.4–5.4 4 18.2 0.7–35.7 2.0 0.7–6.0 <0.001
HPV58  599 19.4 18.0–20.8 1 14 20.3 10.5–30.0 1.1 0.6–1.9 14 27.4 14.8–40.1 1.6 0.8–2.9 6 27.3 7.1–47.5 1.5 0.6–4.0 0.109
HPV59  379 12.3 11.1–13.4 1 12 17.4 8.2–26.6 1.5 0.8–2.8 11 21.6 9.9–33.2 2.0 1.0–3.9 5 22.7 3.7–41.7 2.1 0.8–5.7 0.007
lr-HPV  1016 32.9 31.2–34.5 1 24 34.8 23.2–46.3 1.1 0.6–1.8 21 41.2 27.2–55.1 1.4 0.8–2.5 8 36.4 14.5–58.2 1.2 0.5–2.8 0.249
Single  lr-HPV 156 5.1 4.4–5.9 1 2 2.9 0.0–6.9 0.5 0.1–2.3 3 5.9 0.0–12.6 1.1 0.3–3.7 1 4.5 0.0–14.0 0.9 0.1–6.6 0.813
Multiple  lr-HPV 857 27.7 26.2–29.3 1 22 31.9 20.6–43.2 1.2 0.7–2.0 18 35.3 21.7–48.9 1.4 0.8–2.5 7 31.8 10.7–52.9 1.2 0.5–3.0 0.185
Only  lr-HPV 203 6.6 5.7–7.4 1 2 2.9 0.0–6.9 0.4 0.1–1.7 3 5.9 0.0–12.6 0.9 0.3–2.9 1 4.5 0.0–14.0 0.7 0.1–5.0 0.408
HPV6  or 11 639 20.7 19.3–22.1 1 16 23.2 13.0–33.4 1.1 0.6–2.0 15 29.4 16.5–42.3 1.6 0.9–2.9 6 27.3 7.1–47.5 1.4 0.5–3.7 0.097
HPV6  and 11 120 3.9 3.2–4.6 1 4 5.8 0.1–11.4 1.5 0.5–4.2 4 7.8 0.2–15.5 2.1 0.7–5.9 2 9.1 0.0–22.1 2.5 0.6–10.7 0.043
HPV6  583 18.9 17.4–20.3 1 15 21.7 11.7–31.7 1.2 0.7–2.1 15 29.4 16.4–42.3 1.8 1.0–3.3 6 27.3 7.1–47.5 1.6 0.6–4.1 0.036
HPV11  176 5.7 4.9–6.5 1 5 7.2 1.0–13.5 1.3 0.5–3.2 4 7.8 0.2–15.5 1.4 0.5–3.9 2 9.1 0.0–22.1 1.6 0.4–7.1 0.289
HPV68  371 12.0 10.9–13.2 1 12 17.4 8.2–26.6 1.5 0.8–2.9 7 13.7 3.9–23.5 1.2 0.5–2.6 2 9.1 0.0–22.1 0.7 0.2–3.1 0.642
HPV73  376 12.2 11.0–13.3 1 9 13.0 4.9–21.2 1.1 0.5–2.2 12 23.5 11.5–35.6 2.2 1.1–4.3 3 13.6 0.0–29.2 1.1 0.3–3.9 0.071
9 women  with atypical glandular cells or atypical squamous cells – cannot exclude HSIL (ASC-H) were excluded from analyses.
Due to antibodies to multiple HPV types present in the serum of one woman the sums may  not add up.
HPV:  human papillomavirus; NILM: negative for intraepithelial lesion or malignancy; ACS-US: atypical squamous cells of undetermined signiﬁcance; LSIL: low-grade squamous intraepithelial lesions.
HSIL: high grade squamous intraepithelial lesion; N: number of seropositive women; S: seropositivity; CI: conﬁdence interval for seropositivity; OR: odds ratio (odds of seropositivity in women  with particular pathological
cytology  result against odds of seropositivity among women  with NILM).
hr-HPV types: high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59 (Group 1 by the IARC Monograph Working Group with the exception of HPV 51)).
lr-HPV types: low-risk HPV types (6, 11, 68, 73).
a Since seroprevalence of HPV infection is common, ORs are not numerically similar to prevalence ratios.
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Fig. 1. Seropositivity (%) for HPV 6, HPV 11, HPV 16 and HPV 18 with 95% conﬁdence938 V.  Ucˇakar et al. / Vac
issing or they have been vaccinated against HPV. The mean age of
he remaining 3259 women was 36.5 years (median: 35). Among
239 women with available cytology result, 95.3% were negative
or intraepithelial lesion or malignancy (NILM), 2.1% had atypical
quamous cells of undetermined signiﬁcance (ACS-US), 0.1% atypi-
al glandular cells, 1.6% low-grade squamous intraepithelial lesions
LSIL), 0.7% high grade squamous intraepithelial lesion (HSIL), and
.2% atypical squamous cells-cannot exclude HSIL (ASC-H).
Table  1 shows the overall seropositivity and age speciﬁc sero-
ositivity for individual HPV types and for different combinations
f HPV types. The overall seropositivity for any of the 15 HPV
ypes was 65.7% (CI:64.0–67.3%), for any of the 11 hr-HPV 59.2%
CI:57.5–60.9%), and any of the four lr-HPV 33.1% (CI:31.5–34.7%).
ntibodies against at least one of the four vaccine HPV types (HPV
, 11, 16, 18) were detected among 40.8% women (CI:39.1–42.5%).
verall seropositivity for multiple HPV types was higher (45.3%;
I:43.6–47.0%) than seropositivity for single HPV types (20.4%;
I:19.0–21.7%). The HPV type speciﬁc seropositivity was  the high-
st for HPV 16 (25.2%; CI:23.7–26.6%), followed by HPV 58 (19.6%;
I:18.3–21.0%), and HPV 6 (19.1%; CI:17.7–20.4%). Seropositivity for
PV 18 was 9.4% (CI:8.4–10.5%), and for HPV 11 5.8% (CI:5.0–6.6%).
Women with at least ﬁve lifetime heterosexual partners had 5.1
95% CI:4.0–6.4) times higher odds for seropositivity with any of
he hr-HPV types in comparison to those with only one heterosex-
al partner ever (p < 0.001) and those with seropositivity for HPV
6 and HPV 18, had 5.3 (CI:4.0–7.0) and 7.6 (CI:4.7–12.3) times
igher odds in comparison to those with only one heterosexual
artner ever (both p < 0.001). Corresponding odds ratios for lr-HPV,
PV 6, and HPV 11 were 4.1 (CI:3.3–5.2), 4.1 (CI:3.1–5.5), and 2.7
CI:1.7–4.4) (all p < 0.001).
The age-speciﬁc seropositivity for HPV 16 increased from 17.8%
mong women 20–24 years old to 32.4% among those 30–34 years
ld (ptrend < 0.001), and then decreased with increasing age to
4.0% among 60–64 years old women (ptrend = 0.014), while the
ge-speciﬁc seropositivity for HPV 18 increased from 5.8% among
omen 20–24 years old to 11.7% among those 25–34 years old
p < 0.001), which was not followed by a decrease with increasing
ge (ptrend = 0.159) (Fig. 1).
Seropositivity for hr-HPV and lr-HPV types according to
ytology result is shown in Table 2. Seropositivity for any of
he 11 hr-HPV was lower among women with NILM (58.3%;
I:56.6–60.1%) than among women with pathological cytology
esults (76.8%; CI:70.0–83.6%; p < 0.001). In comparison to women
ith NILM, women with ASC-US had 2.2 (CI:1.2.-3.8) times higher
dds for seropositivity for any of the hr-HPV types, women with
SIL 2.9 (CI:1.4–5.9) times, and women with HSIL 2.4 (CI:0.9–6.6)
imes higher odds (ptrend < 0.001). Increasing seropositivity with
ncreasing pathology of the cytology result was observed for the
ajority of individual hr-HPV types.
. Discussion
We  obtained the ﬁrst seroprevalence estimate for as many as 15
elected genital HPV types in a survey of 3259 Slovenian women
0–64 years old screened for cervical cancer, the largest such
opulation-based cross-sectional study to date.
Comparison of reported results of different HPV seroepidemio-
ogical studies should be done with caution, because of differences
n study periods, age range of the studied populations, and the
ethods used for detecting HPV type speciﬁc antibodies. Our
verall seroprevalence estimate for any of the 11 hr-HPV types
xamined was high in comparison to other similar studies [9–14].
he HPV 16 seroprevalence was higher than in all similar stud-
es. Also our HPV 18 seroprevalence estimate was the highest,
xcept for the Czech study [14]. We  observed a higher proportionintervals according to age among 3259 women screened for cervical cancer, Slovenia,
2010.
of women  with antibodies against multiple HPV types than against
single HPV types. Some overestimation of seropositivity to mul-
tiple HPV types could be attributed to a possible cross-reactivity
of HPV speciﬁc antibodies induced by infection with phylogeneti-
cally related HPV types [11,12]. However, our method had a high
speciﬁcity and low cross-reactivity [8]. The association of seroposi-
tivity with higher numbers of lifetime sexual partners suggests that
cine 3
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e have used a speciﬁc assay [9,10,12]. As others, we also showed
ower seroprevalence for any of the 11 hr-HPV types among women
ith NILM in comparison to women with pathological cytology
esults [19,20].
The  decreasing seropositivity for any HPV and many individual
PV types with increasing age in women after their thirties seems
o be mainly due to a cohort effect and not to waining antibody
esponse. Women  born during 1950-ties and 1960-ties reported
ower numbers of lifetime male partners and were thus at a lower
umulative lifetime risk for HPV infection in comparison to women
orn during 1970-ties that were 30–39 years old at the time of the
urvey (results not shown).
Possible constrain in extrapolating our results to all Slovenian
omen 20–64 years old is the possibility that women  who are
ot screened for cervical cancer are at a different risk of natu-
al exposure to HPV infection. However, we were able to ensure
hat with respect to age and cervical pathology, our study popu-
ation had fairly similar characteristics to the total population of
omen screened for cervical cancer during 2010 and with respect
o age, to Slovenian women 20–64 years old (results not shown).
lso, measuring HPV type speciﬁc antibodies underestimates the
umulative lifetime risk of infections, as not all infected individ-
als develop detectable levels, antibodies can be detected only
everal months after infection, and because of waning of sero-
ositivity [6,7]. However, we believe that our estimates fairly
ell reﬂect the substantial burden of lifetime sexually transmit-
ed infections with the examined 15 HPV types in the reference
opulation.
We have shown a substantial cumulative lifetime sexual expo-
ure to at least one of the 15 HPV types examined as well as a
elatively high cumulative lifetime sexual exposure to at least one
f the four vaccine HPV types among Slovenian women. Thus, vac-
ination of females before sexual debut with a quadrivalent HPV
accine has a potential to contribute to a substantial reduction
f the burden of cervical infections and cervical cancer as well as
ome other HPV related morbidity, including genital warts among
omen and their male sexual partners.
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